Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants

Critical Care Clinics

Volumn 21, Issue 3 SPEC. ISS., 2005, Pages 497-512

  DeLoughery, Thomas G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 9 COMPLEX; CLOPIDOGREL; DALTEPARIN; DANAPAROID; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HEPARIN LYASE; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICLOPIDINE; TINZAPARIN; TIROFIBAN; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 21244464753     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2005.05.004     Document Type: Review

References (132)

1. D.R. Hirsch, E.P. Ingenito, and S.Z. Goldhaber Prevalence of deep venous thrombosis among patients in medical intensive care JAMA 274 1995 335 337
2. P.E. Marik, L. Andrews, and B. Maini The incidence of deep venous thrombosis in ICU patients Chest 111 1997 661 664
3. B.M. Legere, R.A. Dweik, and A.C. Arroliga Venous thromboembolism in the intensive care unit Clin Chest Med 20 1999 367 384
4. E.H. Ibrahim, M. Iregui, and D. Prentice Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis Crit Care Med 30 2002 771 774
5. J. Attia, J.G. Ray, and D.J. Cook Deep vein thrombosis and its prevention in critically ill adults Arch Intern Med 161 2001 1268 1279
6. W.H. Geerts, G.F. Pineo, and J.A. Heit Prevention of venous thromboembolism Chest 126 Suppl 2004 338S 400S
7. P. Thorborg Bleedings and thrombosis in critical care patients: - an update Critical Care and Shock 1 2000 4 10
8. W. Geerts, and R. Selby Prevention of venous thromboembolism in the ICU Chest 124 Suppl 2003 357S 363S
9. A. Leizorovicz, and P. Mismetti Preventing venous thromboembolism in medical patients Circulation 110 2004 IV13 IV19
10. D.G. Jacobs, J.J. Piotrowski, and D.A. Hoppensteadt Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: preliminary results J Trauma 40 1996 710 716
11. F. Allenby, L. Boardman, and J.J. Pflug Effects of external pneumatic intermittent compression on fibrinolysis in man Lancet 2 1973 1412 1414
12. R. Collins, A. Scrimgeour, and S. Yusuf Reduction in fatal pulmonary embolism and venous thrombosis by perioperative adminstration of subcuaneous heparin N Engl J Med 318 1988 1162 1172
13. V.V. Kakkar, T.P. Corrigan, and D.P. Fossard Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial Lancet 1 1977 567 569
14. S. Noble, D.H. Peters, and K.L. Goa Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease Drugs 49 1995 388 410
15. M.M. Samama, A.T. Cohen, and J.Y. Darmon A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N Engl J Med 341 1999 793 800
16. N.A. Reynolds, C.M. Perry, and L.J. Scott Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery Drugs 64 2004 1575 1596
17. J. Hirsh, J.E. Dalen, and D. Anderson Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range [abstract] Chest 114 Suppl 1998 445S 469S
18. W.H. Geerts, R.M. Jay, and K.I. Code A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma N Engl J Med 335 1996 701 707
19. G. Agnelli, F. Piovella, and P. Buoncristiani Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery N Engl J Med 339 1998 80 85
20. A. Perrier, and H. Bounameaux Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism Thromb Haemost 86 2001 475 487
21. C. Kearon, J.S. Ginsberg, and J. Hirsh The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism Ann Intern Med 129 1998 1044 1049
22. J.F. Polak Doppler ultrasound of the deep leg veins. a revolution in the diagnosis of deep vein thrombosis and monitoring of thrombolysis Chest 99 Suppl 1991 165S 172S
23. B.G. Birdwell, G.E. Raskob, and T.L. Whitsett The clinical validity of normal compression ultrasonography in outpatients suspected of raving deep venous thrombosis Ann Intern Med 128 1998 1 7
24. M. Riedel Acute pulmonary embolism 1: pathophysiology, clinical presentation, and diagnosis Heart 85 2001 229 240
25. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax 58 2003 470 483
26. U.J. Schoepf, S.Z. Goldhaber, and P. Costello Spiral computed tomography for acute pulmonary embolism Circulation 109 2004 2160 2167
27. U.J. Schoepf, and P. Costello CT angiography for diagnosis of pulmonary embolism: state of the art Radiology 230 2004 329 337
28. A.A. Donato, J.J. Scheirer, and M.S. Atwell Clinical outcomes in patients with suspected acute pulmonary embolism and negative helical computed tomographic results in whom anticoagulation was withheld Arch Intern Med 163 2003 2033 2038
29. J.D. Prologo, R.C. Gilkeson, and M. Diaz The effect of single-detector CT versus MDCT on clinical outcomes in patients with suspected acute pulmonary embolism and negative results on CT pulmonary angiography AJR Am J Roentgenol 184 2005 1231 1235
30. M.M.W. Koopman, P. Prandoni, and F. Piovella Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home N Engl J Med 334 1996 682 687
31. G.E. Raskob Heparin and low molecular weight heparin for treatment of acute pulmonary embolism Curr Opin Pulm Med 5 1999 216 221
32. G.F. Pineo, and R.D. Hull Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism Bail Clin Haem 11 1998 621 637
33. H.R. Buller, G. Agnelli, and R.D. Hull Antithrombotic therapy for venous thromboembolic disease Chest 126 Suppl 2004 401S 428S
34. R.E. Schutgens, E.U. Esseboom, and R.J. Snijder Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism J Lab Clin Med 144 2004 100 107
35. D.J. Quinlan, A. McQuillan, and J.W. Eikelboom Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Ann Intern Med 140 2004 175 183
36. H.R. Buller, B.L. Davidson, and H. Decousus Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 2003 1695 1702
37. J.Y.V. Yee, and S.B. Duffull The effect of body weight on dalteparin pharmacokinetics - A preliminary study Eur J Clin Pharmacol 56 2000 293 297
38. W. Lim, D.J. Cook, and M.A. Crowther Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials J Am Soc Nephrol 15 2004 3192 3206
39. S.M. Arcasoy, and J.W. Kreit Thrombolytic therapy of pulmonary embolism - A comprehensive review of current evidence Chest 115 1999 1695 1707
40. M. Riedel Acute pulmonary embolism 2: treatment Heart 85 2001 351 360
41. S. Wan, D.J. Quinlan, and G. Agnelli Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials Circulation 110 2004 744 749
42. D.S. Kanter, K.M. Mikkola, and S.R. Patel Thrombolytic therapy for pulmonary embolism - frequency of intracranial hemorrhage and associated risk factors Chest 111 1997 1241 1245
43. M.B. Streiff Vena cava filters: a comprehensive review Blood 95 2000 3669 3677
44. M.B. Streiff Vena cava filters: a review for intensive care specialists J Intensive Care Med 18 2003 59 79
45. H. Decousus, A. Leizorovicz, and F. Parent A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis N Engl J Med 338 1998 409 415
46. R.H. White, H. Zhou, and J. Kim A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism Arch Intern Med 160 2000 2033 2041
47. P.D. Stein, M. Alnas, and E. Skaf Outcome and complications of retrievable inferior vena cava filters Am J Cardiol 94 2004 1090 1093
48. P.D. Stein, F. Kayali, and R.E. Olson Twenty-one-year trends in the use of inferior vena cava filters Arch Intern Med 164 2004 1541 1545
49. J.F. Timsit, J.C. Farkas, and J.M. Boyer Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis Chest 114 1998 207 213
50. E. Cobos, S. Dixon, and Y.K. Keung Prevention and management of central venous catheter thrombosis Curr Opin Hematol 5 1998 355 359
51. O. Durbec, X. Viviand, and F. Potie A prospective evaluation of the use of femoral venous catheters in critically ill adults Crit Care Med 25 1997 1986 1989
52. M.E. Tesselaar, J. Ouwerkerk, and M.A. Nooy Risk factors for catheter-related thrombosis in cancer patients Eur J Cancer 40 2004 2253 2259
53. V.L. Hoshal, R.G. Ause, and P.A. Hoskins Fibrin sleeve formation on indwelling subclavian central venous catheters Arch Surg 102 1971 353 358
54. P.F. Hoar, G. Stone, and A.E. Wicks Thrombogenesis associated with Swan-Ganz catheters Anesthesiology 48 1978 445 447
55. G.M. Joynt, J. Kew, and C.D. Gomersall Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients Chest 117 2000 178 183
56. J. Merrer, J.B. De, and F. Golliot Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial JAMA 286 2001 700 707
57. M.M. Bern, J.J. Lokich, and S.R. Wallach Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial Ann Intern Med 112 1990 423 428
58. P. Boraks, J. Seale, and J. Price Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies Br J Haematol 101 1998 483 486
59. M. Verso, G. Agnelli, and S. Bertoglio Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients J Clin Oncol 2005 in press
60. S. Couban, M. Goodyear, and M. Burnell Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer J Clin Oncol 2005 in press
61. R.P. Rosovsky, and D.J. Kuter Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management Hematol Oncol Clin N Am 19 2005 183 202
62. R.A. Reiter, F. Mayr, and H. Blazicek Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin Blood 102 2003 4594 4599
63. F.W. Peter, C. Benkovic, and T. Muehlberger Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction Br J Haematol 117 2002 658 663
64. P.A. Flordal Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin Eur J Anaesthesiol Suppl 14 1997 38 41
65. W.S. Schroeder, and P.J. Gandhi Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents Curr Cardiol Rep 5 2003 310 317
66. T. Ibbotson, J.K. McGavin, and K.L. Goa Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation Drugs 63 2003 1121 1163
67. Y.F. Li, F.A. Spencer, and R.C. Becker Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition Am Heart J 143 2002 725 732
68. R. Reiter, P. Jilma-Stohlawetz, and M. Horvath Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide Transfusion 45 2005 420 426
69. S. Voutilainen, T.A. Lakka, and P. Hamelahti Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic heart disease risk factor study J Intern Med 248 2000 217 222
70. M.W. McClure, S.D. Berkowitz, and R. Sparapani PURSUIT I: Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome - The platelet glycoprotein IIb IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience Circulation 99 1999 2892 2900
71. S.D. Berkowitz, D.C. Sane, and K.N. Sigmon Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization J Am Coll Cardiol 32 1998 311 319
72. P.A. Merlini, M. Rossi, and A. Menozzi Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 2004 2203 2206
73. M. Makris, and H.G. Watson The management of coumarin-induced over-anticoagulation Annotation Br J Haematol 114 2001 271 280
74. C.T. Taylor, E.A. Chester, and D.C. Byrd Vitamin K to reverse excessive anticoagulation: a review of the literature Pharmacother 19 1999 1415 1425
75. 1 in reversing excessive oral anticoagulation Am J Cardiol 83 1999 286 288
76. A.M. Whitling, H.I. Bussey, and R.M. Lyons Comparing different routes and doses of phytonadione for reversing excessive anticoagulation Arch Intern Med 158 1998 2136 2140
77. S.E. Wilson, H.G. Watson, and M.A. Crowther Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review CMAJ 170 2004 821 824
78. C.J. Possidente, J.G. Howe, and M. Cushman Evaluation of very low-dose subcutaneous vitamin K during postoperative warfarin therapy Pharmacother 21 2001 295 300
79. A. Hung, S. Singh, and R.C. Tait A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization Brit J Haem 109 2000 537 539
80. D.L. Riegert-Johnson, and G.W. Volcheck The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review Ann Allergy Asthma Immunol 89 2002 400 406
81. H.G. Watson, T. Baglin, and S.L. Laidlaw A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin Br J Haematol 115 2001 145 149
82. R.C. Shields, R.D. McBane, and J.D. Kuiper Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy Mayo Clin Proc 76 2001 260 266
83. G. Raj, R. Kumar, and W.P. McKinney Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione [erratum appears in Arch Intern Med 2000;160(7):986] Arch Intern Med 159 1999 2721 2724
84. A.C. Butler, and R.C. Tait Management of oral anticoagulant-induced intracranial haemorrhage Blood Rev 12 1998 35 44
85. C.J. Estol, and C.S. Kase Need for continued use of anticoagulants after intracerebral hemorrhage Curr Treat Options Cardiovasc Med 5 2003 201 209
86. I.C. Nitu, D.J. Perry, and C.A. Lee Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal Clinical & Laboratory Haematology 20 1998 363 367
87. M. Cartmill, G. Dolan, and J.L. Byrne Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies Br J Neurosurg 14 2000 458 461
88. M. Yasaka, T. Sakata, and K. Minematsu Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication Thromb Res 108 2002 25 30
89. D.A. Taberner, J.M. Thomson, and L. Poller Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal BMJ 2 1976 83 85
90. M. Makris, M. Greaves, and W.S. Phillips Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy Thromb Haemost 77 1997 477 480
91. T.E. Warkentin, and M.A. Crowther Reversing anticoagulants both old and new Can J Anaesth 49 2002 S11 S25
92. R.A. Deveras, and C.M. Kessler Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate [summary for patients in Ann Intern Med. 2002;37(11):I41; PMID: 12459002] Ann Intern Med 137 2002 884 888
93. E. Berntorp Recombinant FVIIa in the treatment of warfarin bleeding Semin Thromb Hemost 26 2000 433 435
94. W.D. Freeman, T.G. Brott, and K.M. Barrett Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage Mayo Clin Proc 79 2004 1495 1500
95. J. Lin, W.C. Hanigan, and M. Tarantino The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings J Neurosurg 98 2003 737 740
96. S.A. Mayer, N.C. Brun, and J. Broderick Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage Stroke 36 2005 74 79
97. S.A. Mayer, N.C. Brun, and K. Begtrup Recombinant activated factor VII for acute intracerebral hemorrhage N Engl J Med 352 2005 777 785
98. J.A. Carr, and N. Silverman The heparin-protamine interaction. A review J Cardiovasc Surg (Torino) 40 1999 659 666
99. P. Monagle, A.D. Michelson, and E. Bovill Antithrombotic therapy in children Chest 119 Suppl 2001 344 370
100. J. Holst, B. Lindblad, and D. Bergqvist Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, logiparin). An experimental investigation in healthy volunteers Blood Coagulation & Fibrinolysis 5 1994 795 803
101. J. Hirsh, T.E. Warkentin, and S.G. Shaughnessy Heparin and low molecular weight heparin Chest 119 2001 64S 94S
102. J. Van Ryn-McKenna, L. Cai, and F.A. Ofosu Neutralization of enoxaparine-induced bleeding by protamine sulfate Thromb Haemost 63 1990 271 274
103. H.J. Ng, L.P. Koh, and L.H. Lee Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin Ann Hematol 82 2003 257 258
104. E.K. Heres, J.C. Horrow, and G.P. Gravlee A dose-determining trial of heparinase-I (Neutralase) for heparin neutralization in coronary artery surgery [table] Anesth Analg 93 2001 1446 1452
105. N.R. Bijsterveld, A.H. Moons, and S.M. Boekholdt Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation 106 2002 2550 2554
106. T. Lisman, N.R. Bijsterveld, and J. Adelmeijer Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux J Thromb Haemost 1 2003 2368 2373
107. P. Boccardo, G. Remuzzi, and M. Galbusera Platelet dysfunction in renal failure Semin Thromb Hemost 30 2004 579 589
108. G.T. Gerotziafas, F. Depasse, and T. Chakroun Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood Thromb Haemost 91 2004 531 537
109. K.L. Kaplan, and C.W. Francis Direct thrombin inhibitors Semin Hematol 39 2002 187 196
110. J.I. Weitz, and M. Crowther Direct thrombin inhibitors Thromb Res 106 2002 V275 V284
111. D. Gustafsson Oral direct thrombin inhibitors in clinical development J Intern Med 254 2003 322 334
112. M. Elg, S. Carlsson, and D. Gustafsson Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor Thromb Res 101 2001 145 157
113. A. Greinacher, and N. Lubenow Recombinant hirudin in clinical practice: focus on lepirudin Circulation 103 2001 1479 1484
114. P. Eichler, H.J. Friesen, and N. Lubenow Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance Blood 96 2000 2373 2378
115. K.G. Fischer Hirudin in renal insufficiency Semin Thromb Hemost 28 2002 467 482
116. R.M. Bauersachs, E. Lindhoff-Last, and A.M. Ehrly Treatment of hirudin overdosage in a patient with chronic renal failure Thromb Haemost 81 1999 323 324
117. R.D. Frank, H. Farber, and I. Stefanidis Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes Kidney Int Suppl 72 1999 S41 S45
118. F. Van de Werf, H.V. Barron, and P.W. Armstrong Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA Eur Heart J 22 2001 2253 2261
119. M.A. Sloan, T.R. Price, and C.K. Petito Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the thrombolysis in myocardial infarction (TIMI) II pilot and randomized clinical trial combined experience Neurology 45 1995 649 658
120. J.H. Gurwitz, J.M. Gore, and R.J. Goldberg Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction Ann Intern Med 129 1998 597 604
121. M.A. Sloan, C.A. Sila, and K.W. Mahaffey Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage Circulation 98 1998 1376 1382
122. N.M.J. Van der Put, T.K.A.B. Eskes, and H.J. Blom Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis Q J Med 90 1997 111 115
123. L.M. Brass, J.H. Lichtman, and Y. Wang Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the cooperative cardiovascular project Stroke 31 2000 1802 1811
124. S.C. Patel, and A. Mody Cerebral hemorrhagic complications of thrombolytic therapy Prog Cardiovasc Dis 42 1999 217 233
125. J.E. Dalen, J.S. Alpert, and J. Hirsh Thrombolytic therapy for pulmonary embolism - is it effective? Is it safe? When is it indicated? Arch Intern Med 157 1997 2550 2556
126. K.M. Mikkola, S.R. Patel, and J.A. Parker Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis Am Heart J 134 1997 69 72
127. G.D. Graham Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data Stroke 34 2003 2847 2850
128. F. Donat, J.P. Duret, and A. Santoni The pharmacokinetics of fondaparinux sodium in healthy volunteers Clin Pharmacokinet 41 Suppl 2 2002 1 9
129. S.R. Mehta, J.W. Eikelboom, and S. Yusuf Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis [comment] Lancet 356 2000 449 454
130. C.F. Richards, and C.P. Cannon Reducing medication errors: potential benefits of bolus thrombolytic agents Acad Emerg Med 7 2000 1285 1289
131. D.C. Sane, R.M. Califf, and E.J. Topol Bleeding during thrombolytic therapy for acute myocardial infarction: mechanism and management Ann Intern Med 111 1989 1010 1022
132. T. Lisman, and P.G. De Groot Mechanism of action of recombinant factor VIIa J Thromb Haemost 1 2003 1138 1139